Cyclerion Therapeutics Inc (CYCN) FinancialsCYCNFinancialCyclerion Therapeutics Inc

Cyclerion Therapeutics Inc (CYCN) generates its revenue primarily from Human Therapeutics, which accounts for 100.0% of total sales, equivalent to $133.00K. Understanding this concentration is critical for investors evaluating how CYCN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Cyclerion Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -98.22%, provide a clear picture of how effectively CYCN converts its operational activities into shareholder value.

In the context of the broader market, CYCN competes directly with industry leaders such as RKTO and LPCN. With a market capitalization of $18.21M, it holds a leading position in the sector. When comparing efficiency, CYCN's gross margin of N/A stands against RKTO's N/A and LPCN's N/A. Such benchmarking helps identify whether Cyclerion Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company's total revenue for Q4 2024 was $1,806,000, showing potential growth, while the gross margin remains strong at 100% in recent quarters, indicating effective cost management despite ongoing losses.